CHowe

Spectrum Pharmaceuticals: Optimistic About Zevalin's Prospects

Zevalin's meager sales have NOTHING to do with Zevalin's efficacy, safety, doctor's desire to use a terrific product or lack of promotion by former companies. It has everything to do with where the treatment is given, i.e, who does/does not provide the therapy (hospitals vs. doctors), and the hospitals' lack of adequate reimbursement to justify providing Zevalin as an option. Due to government reimbursement policies, the hospital can actually lose money on a $25,000+ therapy. So very few hospitals want to or do offer it outside academic or teaching hospitals. Just filling in some info missing in the interest of full disclosure.
From a former VP of Sales responsible for Zevalin